Table 4.
Generalized linear model: patient-based changes in disease-specific costs.
| Exponential of Wald 95% confidence limits | p value | |||||
|---|---|---|---|---|---|---|
| Parameters | Parameter estimate | Standard error | Exponential of parameter est. | Lower limit | Upper limit | |
| Euflexxa compared with Supartz/Hyalgan | 0.021 | 0.022 | 1.022 | 0.979 | 1.067 | 0.3304 |
| Synvisc compared with Supartz/Hyalgan | 0.086 | 0.015 | 1.090 | 1.058 | 1.123 | <0.0001* |
| Orthovisc compared with Supartz/Hyalgan | 0.065 | 0.023 | 1.068 | 1.020 | 1.117 | 0.0050* |
*
Statistically significant at alpha level of 0.05.